CWCharles Wu

Charles Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Charles Wu has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular Identification of Kava-Kava (Piper methysticum G. Forst.) Using the Internal Transcribed Spacer (ITS2) Region

    by Iffat Parveen, Natascha Techen, Sara M. Handy, Jing Li, Charles Wu, Amar G. Chittiboyina, Ikhlas A. Khan

    Background: Piper is one of the largest genera in the family Piperaceae, with approximately 2100 species. Most Piper species are used as spices or as medicinal plants. Piper methysticum G. Forst., popularly known as kava-kava (or kava), is widely used to treat anxiety disorders. Due to similar morphological features, P. auritum Kunth (known as “false kava”) is sometimes mistakenly or intentionally used as an alternative botanical source for “kava” extracts. The false kava extracts do not contain active kavalactones but contain safrole, which is hepatotoxic. It is important to verify the component botanical materials in order to evaluate the quality and safety attributes of a potential botanical drug. Some studies have evaluated genetic variation in Piper sp. using the chloroplast regions matK, rbcL, rpoC1 and trnH-psbA and the nuclear ITS2 markers. However, none has focused on the identification of P. methysticum using DNA barcodes. In the present investigation, the ITS2 DNA barcode region from the nuclear genome was tested to confirm the identification and authentication of kava-kava samples. Methods: Seven P. methysticum samples were collected from three different geographic lo-cations and two P. auritum samples were collected and the ITS2 region from the nuclear genome, was amplified, sequenced and aligned to determine their genetic distances. Results: The ITS2 locus showed high amplification and sequence output with a discriminating barcode gap. A distance-based phylogenetic tree and BLAST confirmation (using blastn) revealed the ITS2 locus as a diagnostic DNA barcode for the accurate identification of kava-kava species. Discussion: In conclusion, the ITS2 region proves to be an effective and reliable DNA barcode for distinguishing P. methysticum from closely related species such as P. auritum. Its application can significantly improve the safety, quality, and traceability of kava-containing products, addressing a critical need in the standardization of botanical drugs.

  • Open Access

    Analysis of Regulatory Botanical Submission Profile for Cancer Management from the U.S. FDA Perspectives

    by Jin-Young K. Park, Daniel Lee, Lixin Rui, Xiaoyue Gao, M. Scott Furness, Charles Wu

    Background: The United States Food and Drug Administration (FDA) has received over 700 botanical investigational new drug applications (INDs) in a broad spectrum of therapeutic areas since 1984. The greatest numbers were for cancer management. The aims of our study were to conduct a first-time, in-depth analysis of the regulatory submission profiles for botanical INDs with oncologic indications, in comparison with non-oncologic indications, and to share our regulatory review experience of oncologic botanical drug research and development. Methods: The FDA Center for Drug Evaluation and Research (CDER) maintains an in-house database of botanical INDs that contains many data elements, including initial 30-day actions (safe-to-proceed, clinical hold, etc.), current regulatory status, primary purpose of the proposed clinical trials, and initially proposed clinical trial phase information by sponsor. The database provided internally validated regulatory submission information that FDA received between March 1984 and December 2020 for 254 botanical INDs with oncologic indications, as well as 485 non-oncologic botanical INDs. Results: A higher percentage of the oncologic botanical INDs (69% versus 58% for non-oncologic botanical INDs, p < 0.01) received an initial 30-day safe-to-proceed designation to initiate the clinical investigations. One hundred thirty-seven oncologic botanical INDs were submitted to conduct phase 1 trials to investigate the safety and tolerability of their products, and 46 of these INDs are currently active. An additional 117 INDs were proposed to conduct phase 2 or phase 3 trials to assess safety and efficacy of oncologic botanical products, and 36 of those INDs are currently active, including 3 INDs in phase 3 trials. Most of the oncologic botanical INDs were for the investigation of specific solid tumors (71%) with more than one third of these related to prostate and breast tumors. Conclusions: Despite the scientific and regulatory challenges that FDA reviewers previously experienced, our analysis shows that there were over 80 currently active botanical oncologic INDs, including several in the late phase of drug development for cancer management. The implication of this finding is significant in that many clinical trials of botanical drug products intended to provide high-quality cancer patient care are in the regulatory pipeline.


  • Open Access

    Recommendations and guidelines of integrative medicine for COVID-19 care: The APEC project outcome

    by Libin Jia, Michelle Beidelschies, Joel M. Evans, Richard C. Niemtzow, Songxuan Zhou Niemtzow, Jeffery A. Dusek, Yufang Lin, Charles Wu, C. Jason Wang, Yi-Chang Su, et al.


  • Open Access

    Chemical Authentication and Speciation of Salvia Botanicals: An Investigation Utilizing GC/Q-ToF and Chemometrics

    by Joseph Lee, Mei Wang, Jianping Zhao, Bharathi Avula, Amar G. Chittiboyina, Jing Li, Charles Wu, Ikhlas A. Khan

    Members of the genus Salvia are used as culinary herbs and are prized for their purported medicinal attributes. Since physiological effects can vary widely between species of Salvia, it is of great importance to accurately identify botanical material to ensure safety for consumers. In the present study, an in-depth chemical investigation is performed utilizing GC/Q-ToF combined with chemometrics. Twenty-four authentic plant samples representing five commonly used Salvia species, viz. S. apiana, S. divinorum, S. mellifera, S. miltiorrhiza, and S. officinalis, are analyzed using a GC/Q-ToF technique. High-resolution spectral data are employed to construct a sample class prediction (SCP) model followed by principal component analysis (PCA) and partial least square discriminant analysis (PLS-DA). This model demonstrates 100% accuracy for both prediction and recognition abilities. Additionally, the marker compounds present in each species are identified. Furthermore, to reduce the time required and increase the confidence level for compound identification and the classification of different Salvia species, a personal compound database and library (PCDL) containing marker and characteristic compounds is constructed. By combining GC/Q-ToF, chemometrics, and PCDL, the unambiguous identification of Salvia botanicals is achieved. This high-throughput method can be utilized for species specificity and to probe the overall quality of various Salvia-based products.


  • Open Access

    The Low Copy Nuclear Gene Region, Granule Bound Starch Synthase (GBSS1), as a Novel Mini-DNA Barcode for the Identification of Different Sage (Salvia) Species

    by Iffat Parveen, Natascha Techen, Sara M. Handy, Jing Li, Charles Wu, Amar G. Chittiboyina, Ikhlas A. Khan

    Morphological similarity within species makes the identification and authentication of Salvia species challenging, especially in dietary supplements that contain processed root or leaf powder of different sage species. In the present study, the species discriminatory power of 2 potential DNA barcode regions from the nuclear genome was evaluated in 7 medicinally important Salvia species from the family Lamiaceae. The nuclear internal transcribed spacer 2 and the exon 9 – 14 region of low copy nuclear gene WAXY coding for granule-bound starch synthase 1 were tested for their species discrimination ability using distance, phylogenetic, and BLAST-based methods. A novel 2-step PCR method with 2 different annealing temperatures was developed to achieve maximum amplification from genomic DNA. The granule-bound starch synthase 1 region showed higher amplification and sequencing success rates, higher interspecific distances, and a perfect barcode gap for the tested species compared to the nuclear internal transcribed spacer 2. Hence, these novel mini-barcodes generated from low copy nuclear gene regions (granule-bound starch synthase) that were proven to be effective barcodes for identifying 7 Salvia species have potential for identification and authentication of other Salvia species.


  • Top Cited Papers

    Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective

    by Charles Wu, Su-Lin Lee, Cassandra Taylor, Jing Li, Yen-Ming Chan, Rajiv Agarwal, Robert Temple, Douglas Throckmorton, Katherine Tyner

    The United States FDA has received over 800 botanical investigational new drug applications (IND) and pre-IND meeting requests (PIND) in the years preceding 2018. The current data show that indications for submitted INDs cover nearly every review division of the FDA. Despite increasing global interest in the investigation of botanical mixtures as drug products, only two botanical new drug applications (NDA) have been approved in the U.S.: Veregen in 2006 and Fulyzaq (also known as Mytesi) in 2012. Given botanicals’ chemical and biological complexity, efforts in characterizing their pharmacology, demonstrating therapeutic efficacy, and ensuring quality consistency remain scientific and regulatory challenges. The FDA published a revised Botanical Drug Development Guidance for Industry document in December 2016 to address developmental considerations for late-phase trials and to provide recommendations intended to facilitate botanical drug development. Herein, we present an analysis of botanical INDs showing their variety of botanical raw materials (e.g., coming from different geographic regions, single vs multiple herbs), the varied levels of previous human experience, and therapeutic areas, as well as provide an overview of experience and challenges in reviewing botanical drugs.